Nine products, five years, three lanes: how Chinese CAR-T went from “can it be approved” to “who can actually deliver”

To understand all the commercial logic that follows, it is worth spending a few minutes getting this clear, because every peculiarity of CAR-T — high price, difficult scale-up, dependence on large hospitals, a fragile supply chain — grows out of its very nature.

It is a “living drug”, not a “chemical”. The vast majority of drugs you know, whether small molecules or monoclonal antibodies, are essentially “standardized chemicals or proteins”: made in batches at a factory, bottled and stocked; patients nationwide use the same batch of the same thing, and physicians can use it as soon as it is prescribed. CAR-T works on a completely different logic. It is a batch of living cells made individually for one patient, from that patient’s own immune cells.

The specific process is this: physicians first collect T cells from the patient through “leukapheresis” and ship them to a factory; at the factory, a viral vector is used to insert an artificially designed gene into the T cells, so that they grow a “chimeric antigen receptor” (CAR) on their surface — this receptor is like a custom radar that specifically recognizes a marker on the surface of tumor cells (such as CD19, BCMA or CLDN18.2); the modified cells are expanded at the factory to a sufficient number, then shipped back to the hospital by cold chain; before reinfusion, the patient usually first undergoes a round of “lymphodepleting chemotherapy” (commonly fludarabine + cyclophosphamide) to make room for the new cells; finally this batch of “modified living cells” is infused back into the patient, where they keep proliferating, patrolling and hunting down cells carrying that marker.

Every word in this chain later becomes a commercial problem. “Taken from the patient, made individually for the patient” — so it cannot be mass-produced and costs are very high; “shipped out and back, time needed for expansion” — so there is a critical “vein-to-vein time” (how many days from blood collection to reinfusion), and for rapidly progressing patients this wait is a matter of life and death; “living cells” — so there is batch-to-batch variability, and the “manufacturing release success rate” (how many batches successfully become qualified product) becomes a hard metric; “keeps proliferating after reinfusion” — so it can trigger violent immune reactions.

Its efficacy logic is also the opposite of ordinary drugs. Ordinary drugs work by “continuous dosing, maintaining concentration”, like chronic disease management, and stop working when stopped. CAR-T is “a one-time infusion, aiming for long-term remission” — ideally one infusion, with the living cells persisting in the body long term, leading to deep remission of the disease and sometimes no relapse for a long time. That is the underlying logic that lets it sell for a million: it is not selling a bottle of drug but a treatment that “may change the course of disease”. But this also means it must prove with long-term follow-up data that “the durable benefit bought by this one infusion” is real, or its high price cannot stand.

It has two unique safety risks that directly determine that it can only be done in large hospitals. The first is cytokine release syndrome (CRS): when large numbers of CAR-T cells activate and kill tumor in the body, they release massive amounts of inflammatory cytokines — mild cases mean fever, severe ones hypotension, hypoxia and multi-organ dysfunction, requiring timely medication (such as tocilizumab) and ICU support. The second is immune effector cell-associated neurotoxicity syndrome (ICANS): presenting with neurological symptoms such as confusion, aphasia and seizures. Both reactions come on fast and can be severe, so hospitals doing CAR-T must have mature hematology/oncology teams, an ICU available at any time, and a full set of capabilities for recognizing and managing CRS/ICANS. This determines at the root: CAR-T is not a drug any hospital can prescribe; it is naturally concentrated in a small number of leading centers.

Putting this together, a CAR-T patient’s real journey looks roughly like this: diagnosed relapsed/refractory, assessed as suitable for CAR-T → leukapheresis at a qualified center → cells shipped by cold chain to the factory, waiting two or three weeks or even longer for manufacturing and QC → often bridging therapy in the meantime to stabilize the disease → cells made and shipped back, lymphodepleting chemotherapy first → reinfusion → inpatient close monitoring, ready at any moment to manage CRS and ICANS → long-term follow-up after discharge, watching how long remission lasts and whether there are late safety issues. The journey takes from just over a month to several months, spanning seven or eight links — collection, logistics, manufacturing, chemotherapy, reinfusion, intensive care and follow-up — and if any one link fails, the whole chain breaks. Traditional treatment with pills and injections never needed such a long and fragile chain — this is precisely the physical starting point of all CAR-T’s commercial problems.

Understand these four points — living drug, one batch per patient, one-time long-term remission, CRS/ICANS — and you understand all the commercial conclusions later in this article. CAR-T’s price, uptake bottleneck, payment problem, center concentration and supply chain fragility — none of these is an accident; all are inevitable projections of its nature. And these 9 Chinese products are nine different answers produced under this set of “physical constraints”.

The generic names of all 9 products end in the same Chinese suffix (the Chinese rendering of “-leucel”), and their brand names also look alike — Yikaida, Carteyva, Fucaso, Yuanruida, Saikaize, Carvykti, Hengkailai, Pulidekai, Kailimei. Similar names easily lead people to think they are “nine brands of the same thing”. Quite the opposite. Put the key information side by side and you will see three completely different commercial storylines.

Launch order by NMPA marketing approval date; prices are public tender/launch prices. Two of the newest products (2025 approvals) have no public pricing yet.

This table can be read from at least three angles.

Read by target, it is three lanes of completely different depth. CD19 has 5 products (axi-cel, relma-cel, inati-cel, Hrain’s and Precision Bio’s), the most crowded red ocean; BCMA has 3 (eque-cel, zevor-cel, cilta-cel), all aimed at multiple myeloma, the battlefield where Chinese CAR-T is most globally competitive and also most cutthroat; CLDN18.2 has only 1 (satri-cel), but it is the historic step that took CAR-T from hematologic malignancies into solid tumors.

Read by company model, it is four completely different playbooks. Axi-cel is “multinational technology import + local JV manufacturing” — Fosun Kite brought Kite/Gilead’s mature product into localized production in China; relma-cel, inati-cel, Hrain’s and Precision Bio’s products are typical “domestic cell therapy platforms”, fully in-house from R&D to manufacturing; cilta-cel is “global co-development” — Legend Biotech teaming up with J&J, the only product of Chinese origin with global evidence and multinational commercialization; eque-cel and zevor-cel represent “biotech R&D + collaboration with a large commercial platform” — IASO tied to Innovent and CARsgen tied to Huadong Medicine, using others’ sales and access capabilities to make up for their own commercialization weaknesses.

Read by time, it is three leaps. In 2021–2023, CD19 in lymphoma and leukemia laid the commercial foundation of Chinese CAR-T, forcing hospitals for the first time to learn the whole process of collection, cold chain, reinfusion, CRS management and long-term follow-up; in 2023–2025, BCMA and later CD19 products poured in, and CAR-T went from “scarce innovation” to “crowded competition”, with products forced to prove themselves on depth of evidence, manufacturing efficiency and price; in 2026, satri-cel succeeded in registering CAR-T in a solid tumor, opening a brand-new but harder battlefield. And the pace is clearly accelerating: two approvals in 2021, new products landing every year since, two approvals in 2025 alone and another in the first half of 2026 — approval itself is becoming more and more “routine”, which is the best footnote to the judgment that “approval is depreciating, delivery is king”.

Below we walk into the three target lanes one by one.

CD19 is where Chinese CAR-T began, and today it is the place with the least room for a premium. Five products are crowded into this lane, covering almost every B-cell malignancy scenario from adult lymphoma and adult leukemia to pediatric leukemia. They best illustrate one thing: once a target has been fully validated, the first-mover dividend decays at a visible speed, and competition slides from an “efficacy narrative” to a “service and price narrative”.

Axi-cel: the significance of the first product was forcing hospitals into the CAR-T era

Axi-cel is one of the first CAR-Ts approved in China, backed by Kite/Gilead’s CD19 CAR-T technology (overseas brand name Yescarta) and Fosun Pharma’s local commercialization capabilities. Its registration study ZUMA-1’s data are still a benchmark today: objective response rate (ORR) 82%, complete response rate (CR) 58%, and at a median follow-up of 51 months, median overall survival of 25.8 months and 4-year survival of 44%. For a population of relapsed/refractory large B-cell lymphoma patients who previously had almost no hope of durable remission, this is a difference of magnitude from “basically hopeless” to “nearly half alive at four years”. (It should be noted that its first approval in 2021 targeted “progression after at least two prior lines of therapy”, essentially a third-line-plus setting; only in 2023 was an earlier second-line LBCL indication added.)

But axi-cel’s real historical significance lies not in how good its own efficacy is, but in forcing the entire hospital system into the CAR-T era. Before it, Chinese hospitals had no process prepared for a “living drug”: how to perform leukapheresis on patients, how to ship cells by cold chain to the factory and back, who manages CRS and ICANS when they flare after reinfusion, how the ICU cooperates, how long-term follow-up is done — this whole set of SOPs was built for the first time by products like axi-cel. That is also the value of the Fosun Kite model: a mature multinational product + local manufacturing + an academic network + patient assistance + local commercial insurance, using a whole combination to solve “accessibility”, not just making the drug. The infrastructure it built first is, to some extent, a “public good” for all the domestic products that followed — latecomers can directly use the collection, reinfusion and CRS management systems hospitals have already run in.

Its problems are equally clear. Behind the RMB 1.2 million price is a very high cost structure, and the first-mover advantage is being diluted little by little by latecomers. The real competition axi-cel faces today is not “whether another CD19 CAR-T has higher efficacy”, but that the whole treatment pathway for second- and third-line lymphoma is being rewritten jointly by bispecific antibodies, ADCs and more domestic CAR-Ts. It must transform from “the first approved product” into “a solution provider for hematologic oncology treatment centers” — whoever offers easier patient management, more substantial assistance programs and broader commercial insurance coverage will hold on to those leading centers.

Relma-cel: the first sample of a domestic platform, betting on “label depth”

Relma-cel is also CD19, but the company story is completely different. It is China’s first independently developed CAR-T and the first approved as a Class 1 biologic, and JW Therapeutics’ narrative is that of a thoroughly domestic cell therapy platform — local development, local manufacturing, continuous indication expansion. The registration study RELIANCE showed ORR of 77.6%, CR of 53.5% and 2-year survival of 69%; on safety, CRS incidence was 47.5% (grade ≥3 only 5.1%) and neurotoxicity 20.3% (grade ≥3 3.4%), relatively clean within the class.

Its strategic choice is “going deeper into the label”: after large B-cell lymphoma, it successively expanded indications to follicular lymphoma, mantle cell lymphoma and other settings, turning itself from a single DLBCL product into a CD19 hematologic malignancy platform product. There is very concrete commercial logic behind this — CAR-T’s biggest cost contradiction is “one batch per patient, a long treatment chain, expensive hospital training”; if one product can cover multiple B-cell malignancies, case volume per center rises more easily, and that expensive production line and complex service capability are more easily amortized. In other words, the broader the label, the higher the reuse rate of the same manufacturing and hospital network — the core means by which domestic platform companies fight “high fixed costs”.

The risk is also plain: CD19 is already China’s most crowded target, latecomers may not be able to shift usage habits already established at leading centers, and “off-the-shelf” drugs such as bispecifics will keep squeezing CAR-T’s position with a lower execution threshold. The key for relma-cel to hold its value is not to retell the old story of “import substitution”, but to prove stable benefit across more subtypes, earlier lines and the real world.

Inati-cel: entering through the hardest population, and the first to push the price below a million

Inati-cel took a differentiated road: its first indication is adult relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), making it China’s first CAR-T approved for leukemia. Compared with large B-cell lymphoma, adult B-ALL patients are fewer, but need is more concentrated and more dangerous — these patients progress extremely fast after relapse, and apart from allogeneic transplant there used to be almost no good options. Its registration study showed ORR of 82.1% and 2-year survival of 55.2%, weighty numbers in such a high-risk population. It then expanded to large B-cell lymphoma, becoming one of the few “leukemia + lymphoma” dual-indication CD19 products in China today. Juventas’s approach is a typical domestic platform playbook: first win a registration position in a clear unmet need with relatively little competition to build credibility, then expand into the larger lymphoma market for volume.

But inati-cel is better remembered for pushing the price to RMB 999,000 — the first domestic CAR-T below a million. This number itself is a signal: when there are 5 CD19 products in the lane, price is no longer just a financial matter but a core weapon for access and uptake. A single B-ALL indication can hardly support a nationwide commercial team, so inati-cel must run on two legs at once — “a lower price + broader indications” — to turn leading centers’ cases into sustainable commercial volume. It also foreshadowed the fiercer price war discussed later.

Hrain’s CD19 CAR-T: a latecomer must answer “why do we still need you”

Hrain’s CD19 CAR-T was approved in July 2025, entering the already crowded second-line-plus large B-cell lymphoma setting. This timing means it enjoys none of CD19’s early dividend; clinicians, hospital administrators and payers will all ask the same question: axi-cel and relma-cel are already here — why do we still need you?

Hrain Biotechnology’s answer is hidden in three places. No lag in efficacy: ORR 75.3%, CR 56.8%, 2-year survival of 64.9% at nearly 21 months’ median follow-up, with 74% of complete responders maintaining long-term CR; safety looks even better — grade ≥3 CRS only 3.7% and grade ≥3 neurotoxicity 0. A story in the process: it is the first domestic CAR-T to use a stably transfected cell line viral process. This detail looks technical but has heavy commercial implications — the biggest headache in CAR-T manufacturing is batch-to-batch variability of viral vectors, and a stable cell line means more standardized and controllable virus production, which in theory improves batch consistency and lowers release failure rates. As discussed earlier, “manufacturing and delivery” is CAR-T’s hardest weak spot; whoever achieves stability on this line builds a barrier in the hardest place. More pragmatic positioning: later CD19 products can hardly tell their story on ORR or CR alone, and must put manufacturing time, release rate, patient assistance, hospital service responsiveness and commercial team execution on the table together.

Hrain’s product situation is more like a price and service competition after the domestic CD19 lane entered maturity. It can expand patient access, but without clear enough differentiation it may be squeezed into a regional, price-driven product.

Precision Bio’s CD19 CAR-T: pediatric B-ALL — the clearest clinical value, the most sensitive payment

Precision Bio’s product targets relapsed/refractory CD19-positive B-ALL in patients aged 3–21, China’s first CAR-T for pediatric/adolescent leukemia. The clinical need in this population is unambiguous: children have very few treatment options after relapse, and deep remission, MRD negativity, bridging to transplant and long-term survival each mean “decades of life” for a patient aged a few years to their teens. The data are bright too — as of April 2024, among 64 subjects the best CR/CRi rate within three months was 90.63%, the MRD-negative rate as high as 98.27%, the complete remission rate 78.13% and median overall survival 23.92 months; and it uses a humanized CD19 scFv, currently the only humanized product aimed at children/adolescents — the point of humanization is to reduce patients’ immune rejection of the CAR structure, helping these living cells persist longer in the body, which matters especially for pediatric patients pursuing long-term cure.

Precision Bio’s choice of this population creates much clearer differentiation than adult DLBCL: pediatric B-ALL cases are concentrated in a few strong hematology centers and children’s hospitals, the pathway is clear and physician acceptance is high. But its commercialization is also more sensitive — family ability to pay, charitable assistance, local supplementary insurance and hospital ethics communication: any one link directly determines whether these children can actually get the treatment. A million-yuan pediatric treatment naturally carries heavier payment pressure than an adult one, because it often falls on an ordinary family. The value of Precision Bio’s product can never be measured by patient numbers alone; it represents a step up in the social and policy value of Chinese CAR-T. The keys next are long-term follow-up, sequencing strategies after relapse, and whether treatment can be extended from a few centers to more standardized pediatric hematology centers.

CD19 lane summary: efficacy is no longer the decider

Put the 5 CD19 products together and a harsh fact emerges: the gaps in their efficacy are now too small to decide who wins. ORRs are all in the 75%–82% range, CRs all in the 53%–58% range, and safety is even cleaner generation by generation. When efficacy converges, competition inevitably slides elsewhere — price (RMB 999,000 vs 1.29 million), manufacturing stability (stable cell line processes), population differentiation (adult vs pediatric, leukemia vs lymphoma), and service responsiveness at the hospital end.

Bigger pressure comes from outside the lane. CD19/CD20 bispecific antibodies are “off-the-shelf”: no need to manufacture individually for each patient, usable as soon as prescribed, with a much lower execution threshold. They are competing head-on with CD19 CAR-T for sequencing positions in relapsed/refractory lymphoma. For CD19 CAR-T to hold its position, it can rely on only one thing — using deep remission and long-term benefit to prove that the complex process of “making a batch of living cells for one patient” is worth the higher price hospitals and payers pay.

If CD19 shows the scale of Chinese CAR-T, BCMA shows its ceiling. All 3 products target relapsed/refractory multiple myeloma and all require progression after at least three prior lines — one of the most competitive CAR-T targets in the world, and the only lane where China has produced a “world-class product”. It also puts a sharp question on the table: when every product’s data are as good as they can get, what actually decides success?

Multiple myeloma is a hematologic cancer that is currently essentially incurable and relapses repeatedly; patients often go through line after line of treatment, and with each relapse one fewer weapon remains. So “can deep remission still be achieved in the last line” is the most rigid need in this disease, and it is where the value of BCMA CAR-T lies — it can deliver another high-quality remission when patients have almost nowhere left to go.

Eque-cel: data almost “maxed out”, yet stuck on continuity of commercialization

Eque-cel is China’s first approved BCMA CAR-T, and the data from its registration study FUMANBA-1 come close to the physical limit of this target: among 103 evaluable patients, ORR 96.1%, stringent complete response/complete response (sCR/CR) rate 77.7%, 94.2% of patients reaching MRD negativity, and all CR/sCR patients MRD-negative; on safety, only 1 of the 105 treated patients had grade ≥3 CRS, and there was no grade ≥3 ICANS. This is a report card that would stand up anywhere in the world — an ORR of 96% means almost every patient responds, an extremely high figure in last-line myeloma.

But what is most worth pondering about eque-cel is not the data but the arrangement between “R&D” and “commercial resources”. IASO Bio provided cell therapy R&D capability, while Innovent at one point provided a stronger commercial platform and capital-market endorsement; the rights relationship between the two was later adjusted. This clearly exposes a structural problem of domestic CAR-T: a company that can only do R&D can hardly close the commercial loop on its own. Even with maxed-out data, for a BCMA CAR-T to really sell at myeloma centers nationwide, it still needs a sales network, payment negotiation, hospital access, medical affairs and manufacturing scale-up — capabilities entirely different from “making the cells”. When the partnership carrying commercialization changes, the product’s uptake pace and channel continuity are affected. Eque-cel’s window: if it can maintain deep responses in the real world and be better suited to China than global peers on price and execution, it can keep a seat in the BCMA lane; otherwise, facing cilta-cel’s global evidence and the squeeze from later bispecifics and trispecifics, it will remain under pressure. (Worth mentioning: IASO is also extending eque-cel into autoimmune disease, which we discuss in the final “new continent” section.)

Zevor-cel: “outsourcing” commercialization to Huadong Medicine was a realistic trade-off

Zevor-cel is China’s fifth CAR-T, developed by CARsgen, with equally beautiful data: at a median follow-up of 20.3 months in Phase 2, ORR 92.2% and ≥CR rate 71.6%, with 100% MRD negativity among those reaching CR or better; the earlier Phase 1 even achieved ORR of 100% and ≥CR of 78.6%; on safety there was no grade 3 or higher CRS and no ICANS — a “highly effective + clean” combination.

Zevor-cel’s real highlight is its business model: in early 2023, CARsgen granted Huadong Medicine exclusive commercialization rights in mainland China, with Huadong paying an upfront of RMB 200 million and registration and sales milestones of up to RMB 1.025 billion. This was a very clear-headed trade-off by a domestic CAR-T platform company — CARsgen’s core capability is its cell therapy R&D platform, especially in the harder solid tumor direction; for nationwide myeloma commercialization, rather than building an expensive army itself, it was better to hand it to a partner like Huadong with mature hospital access, channels and payment negotiation capabilities. Priced at RMB 1.15 million, market expectations for its peak sales once exceeded RMB 1 billion.

The significance of this choice goes beyond zevor-cel itself. CARsgen has long made solid tumor CAR-T its biggest narrative (satri-cel, discussed later, is its work), and zevor-cel’s commercial landing in hematologic malignancies is, to some extent, a credibility endorsement of whether the whole platform “can turn products into revenue”. How well it sells will directly affect capital markets’ trust in CARsgen’s solid tumor story. And in fact, the marketing authorization holder for both zevor-cel and satri-cel is CARsgen’s CARsgen Life Sciences — one company, using the same manufacturing and quality system, carrying two burdens at once: BCMA commercialization in China and the global breakthrough in solid tumors.

Cilta-cel: the most successful globally, yet “invisible” in China — the most glaring contrast

Ciltacabtagene autoleucel (cilta-cel overseas) is the most globalized of these 9 products, and the most intriguing. Co-developed by Legend Biotech and J&J, it was approved in the US back in March 2022, then won approvals in the EU and Japan, and was approved in China in August 2024. It has what no other Chinese CAR-T has: full endorsement from global clinical trials, global regulators and a multinational commercial system. Its commercial results are also striking — global net sales reached about US$1.9 billion in 2025, and about US$597 million in Q1 2026 alone, still growing rapidly year on year; it has become a global CAR-T product approaching the US$2 billion level, one of the most dazzling examples of Chinese innovative drugs going global.

But bring the camera back to China, and the picture is completely reversed. Cilta-cel is priced at US$465,000 per infusion in the US, while its pricing and uptake in China are very sparsely disclosed, and its domestic commercial presence after approval is clearly weaker than its overseas performance. A CAR-T of Chinese origin selling nearly US$2 billion globally is barely heard of in its home market.

This contrast is the single most worth pausing on in this whole article. It shows that global capability and China commercialization capability are two different things. Cilta-cel’s value is anchored in high-payment-capacity markets in Europe and the US, and the pricing logic of US$465,000 simply doesn’t work in China — Chinese myeloma patients face domestic BCMA products at RMB 1.15 million and 1.166 million, and the reality that “it’s not on the basic NRDL, and cilta-cel isn’t even on the commercial insurance list”. For Legend/J&J, CAR-T capacity is scarce to begin with (it has to be made individually for each patient), so prioritizing overseas markets with stronger payment capacity and higher unit prices is an understandable commercial choice; whether, and when, to invest more in the Chinese market remains to be seen. Cilta-cel is the most successful benchmark for Chinese innovative drugs going global, but its commercial presence in China is clearly weaker than overseas, which is exactly the reminder: success abroad and commercial success at home can be two curves that don’t overlap.

BCMA lane summary: the sequencing war in multiple myeloma has only just begun

All three BCMA products have data close to the ceiling, which actually makes differentiation harder — everyone has ORR above 90% and very high MRD-negative rates, and on data alone it is almost impossible to tell them apart. What is really reshaping this lane is the increasingly complex treatment sequencing in multiple myeloma: CD38 antibodies, BCMA bispecifics, GPRC5D bispecifics, FcRH5 bispecifics, plus CAR-T itself, with all these therapies moving continually into earlier lines — each of them will compete for the position BCMA CAR-T currently holds. BCMA bispecifics are especially dangerous, because they are also “off-the-shelf”, with an execution threshold far below CAR-T; patients don’t have to wait for manufacturing and hospitals don’t have to build such a heavy process.

So the three products each stand at a different cliff edge: eque-cel must solve continuity of commercialization and find a second growth curve such as autoimmunity; zevor-cel must prove that “outsourced commercialization” works; cilta-cel must answer “whether the global benchmark wants to, and will, invest more in the Chinese market”. What they all face is a myeloma treatment landscape still evolving dramatically and far from settled.

On June 22, 2026, satricabtagene autoleucel was approved. The weight of this approval exceeds any before it — it is the world’s first approved solid tumor CAR-T, breaking the spell that had hung over the whole industry for years: “CAR-T can only treat hematologic cancers”.

Why solid tumors are so hard, and how satri-cel got through

Hematologic cancers are CAR-T’s “home ground”: tumor cells float in the blood and bone marrow, and CAR-T can reach them as soon as it is infused; targets such as CD19 and BCMA are relatively specific in expression and testing is mature. Solid tumors are an “away game”, and almost every step is harder: the tumor grows into a solid mass that CAR-T must first “infiltrate”; the tumor is surrounded by a powerful immunosuppressive microenvironment that leaves CAR-T unable to fight even once inside, and quickly exhausted; antigen expression in solid tumors is often heterogeneous (some cells have it, some don’t), making it easy to miss; and worse, many solid tumor targets are also expressed on normal tissue, so any misdirected attack means potentially fatal “on-target, off-tumor toxicity”. These obstacles stacked up to keep solid tumor CAR-T stuck for more than a decade at the stage of “very promising but just can’t get approved”.

Satri-cel’s choice of CLDN18.2 as the breakthrough point makes sense: in normal gastric mucosa this antigen is “hidden” within the tight junction structure between cells and not easily reached by CAR-T, but becomes exposed after malignant transformation — naturally forming a relatively safe therapeutic window; meanwhile, gastric cancer has a huge patient base in China with very strong unmet need in advanced disease. Its registration study is a randomized controlled Phase 2 (CT041-ST-01) led by Professor Shen Lin’s team at Peking University Cancer Hospital, with main results published in The Lancet and presented orally at ASCO 2025 (the team’s earlier exploratory solid tumor CAR-T results also appeared in Nature Medicine) — in patients with CLDN18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma who had failed at least two prior lines, median progression-free survival was 4.37 months with satri-cel vs 1.84 months with control (hazard ratio 0.30), and median overall survival 8.61 vs 5.49 months (hazard ratio 0.60); on safety, only 4 patients had grade ≥3 CRS, with no grade 4–5 CRS and no ICANS.

These numbers must be viewed very objectively: a median PFS of 4.37 months is not long in absolute terms — that is the real background of the extremely difficult population of third-line-plus advanced gastric cancer, and no one should read it as “gastric cancer conquered”. But the key lies in the hazard ratios — cutting the risk of progression/death by 70% and the risk of death by 40%, and the first time such results were obtained in a solid tumor with a “living drug” in a randomized controlled study. What it proves is not “cure”, but that “solid tumor CAR-T can pass a rigorous registration path and beat standard therapy in a randomized controlled trial” — the significance of this 0-to-1 step can hardly be overstated. Priced at RMB 990,000, it is in the same order of magnitude as hematologic CAR-Ts.

After breaking the ice, commercialization is actually harder

But “registration success” and “commercial success” must be separated — especially important for satri-cel, because commercializing in solid tumors is clearly harder than in hematologic cancers, with at least three hurdles.

First, testing is a hard threshold. Satri-cel is only for CLDN18.2-positive patients, meaning every candidate must first undergo CLDN18.2 immunohistochemistry. Yet CLDN18.2 testing antibodies, scoring thresholds (cutoffs) and concordance between pathology centers are still not fully standardized — the same patient may be judged positive or negative at different hospitals, directly determining whether they can get the drug. Uneven testing capacity will be the first gate on satri-cel’s real accessibility. The good news is that Astellas’s CLDN18.2 monoclonal antibody zolbetuximab (Vyloy) was approved in China for first-line gastric cancer at the end of 2024 and wrote its first prescriptions in 2025, gradually rolling out CLDN18.2 testing infrastructure to pathology departments nationwide — actually a help to satri-cel, since although their lines differ (zolbetuximab in first line, satri-cel after second line), they share the same testing infrastructure, and the road paved by the former can be used by the latter.

Second, patient condition is a practical constraint. Patients with third-line-plus advanced gastric cancer have poor performance status, rapidly progressing disease and often very poor nutrition. And CAR-T requires collection first, then time for manufacturing, then reinfusion — for a patient who may deteriorate rapidly during the wait, the “manufacturing time window” is not a technical detail at all, but a life-or-death question of “whether they can hold out for treatment”. Hematologic cancer patients can still use bridging therapy to buy time; advanced gastric cancer patients have a narrower window, which will genuinely limit how many patients can complete the full process.

Third, competition will quickly become complex. CLDN18.2 is one of the hottest solid tumor targets right now, with monoclonal antibodies (zolbetuximab marketed), ADCs, bispecifics and immunotherapy combinations all crowding in. Satri-cel’s unique value is “deep remission + one-time treatment”, but it has to compete for patients and sequencing positions against these “off-the-shelf + repeatable dosing + earlier line” options, and the pressure is considerable. What it needs to prove is: over a patient’s entire treatment journey, placing CAR-T at a certain point is worth more than using off-the-shelf drugs all the way.

So satri-cel’s real significance is opening a door for solid tumor cell therapy in China; and its commercial ceiling depends on whether testing can be standardized, whether the manufacturing window can be compressed, whether center execution can scale, and whether combination treatment can keep improving. It is a milestone, but after the milestone comes a longer road — and on this road, CARsgen has to walk while clearing mines for the whole industry.

Having walked through the three domestic lanes, it’s worth looking up at the world to see where these 9 products actually stand.

Globally, only a dozen or so CAR-T products have been approved, concentrated mainly in the US, EU, China and Japan, with targets heavily concentrated on CD19 and BCMA. China approved 9 in five years — the fastest-growing market in the world for CAR-T approvals, bar none. Behind this are several uniquely Chinese drivers: a huge patient base, expedited review pathways such as conditional approval, a large number of domestic biotechs focused on cell therapy, and a relatively active clinical research ecosystem.

But “leading in numbers” does not equal “leading in capability”; placing China’s 9 products on global coordinates reveals three layers of reality.

First layer: in “follower innovation”, China has reached first-tier efficiency globally. CD19 and BCMA are both targets first validated in the West, and Chinese products are no worse on data — eque-cel’s ORR of 96% and zevor-cel’s 100% MRD-negative rate would stand up in any comparable study worldwide. China’s advantage is “faster, more, cheaper”: faster at turning validated targets into products, more companies entering at once, and driving prices down from Western levels of hundreds of thousands of dollars to a million yuan, and lower still.

Second layer: in “original breakthroughs”, China has just handed in its first world-class answer. Satri-cel is the world’s first approved solid tumor CAR-T — in this direction, the West is also still struggling near the starting line. This is the first time Chinese CAR-T has not “followed” but “led”. If solid tumor CAR-T can keep going, it may well become China’s real trump card on the global cell therapy map, because it addresses a problem the whole world has yet to solve.

Third layer: in “global commercialization”, China has only one success story — and it is absent at home. Cilta-cel proved Chinese CAR-T can sell on the order of nearly US$2 billion globally, but it relied on J&J’s global system, and that success is almost disconnected from the domestic Chinese market. Apart from cilta-cel, the value of the other 8 products is currently essentially locked in China. That is, Chinese CAR-T already leads in “able to make it, approved fast, sold cheap”, but has only just started on “selling products globally and earning a high premium back from global markets”.

These three layers correspond precisely to the three inflection points discussed later: the price war, next-generation technology and going global.

Having walked through the three lanes, you find that whether CD19, BCMA or CLDN18.2, whether multinational import or domestic in-house, these 9 products are all tightly held by the same five constraints. These five hidden threads are the real key to understanding Chinese CAR-T — because what they determine is not “can it be approved”, but “can it survive after approval”. And you will find they all grow out of the essence discussed in Part 1 — “living drug, one batch per patient”.

Thread one: manufacturing and delivery are CAR-T’s lifeline

The most fundamental difference between autologous CAR-T and traditional drugs is that it is not a standard product “ready to use from the factory”, but a batch of living cells per patient. On this chain there are two metrics almost every company is tight-lipped about: vein-to-vein time (how many days from blood collection to reinfusion) and manufacturing release success rate (how many batches successfully become qualified product, and how many fail). They directly determine commercial delivery capability, yet stable disclosures of these numbers are almost nowhere to be found in public materials.

This is no coincidence — precisely because they are so critical and so unflattering, they have become the industry’s tacit black box. Imagine a real scenario: a rapidly progressing patient completes collection and waits for reinfusion, only for that batch of cells to fail manufacturing, or fail release because viability is below standard, requiring re-collection and remanufacturing — in those extra two or three weeks, the disease may already have closed the window. Every percentage point higher in the release failure rate means specific patients who couldn’t wait for the drug. So Hrain’s use of a “stably transfected cell line viral process” as a selling point and Fosun Kite’s emphasis on local manufacturing technology transfer capability are both, in essence, working on this line: whoever makes manufacturing more stable, with less batch-to-batch variation, lower failure rates and shorter cycles, builds a moat in the hardest and least sexy place in CAR-T. This is also why next-generation “universal/off-the-shelf CAR-T” could be disruptive — it tries to dismantle this fragile chain entirely.

Thread two: the center network decides whether “the market is huge” is an illusion

CAR-T is not something any hospital can do. As discussed, it requires ICU support, mature hematology/oncology teams, the ability to recognize and manage CRS and ICANS, cell collection and processing conditions, and a long-term follow-up system. This means centers able to execute CAR-T reliably are highly concentrated in a small number of leading hospitals.

This creates a paradox: China’s patient base looks enormous, but the centers that can actually take on CAR-T are few. Concentration at the top is an efficiency advantage early on — educate a few centers and volume starts; but it is also a ceiling — to scale nationally, certified centers must expand from dozens to hundreds, and each additional one means rebuilding SOPs, training teams, equipping the ICU and getting payment to work, a slow and expensive process. For pediatric B-ALL (Precision Bio) and solid tumors (satri-cel), this problem is sharper, because qualified pediatric hematology centers and centers able to do solid tumor cell therapy are fewer, with higher thresholds, than adult lymphoma centers. So for any CAR-T product, “how many centers with execution capability it covers, and how many cases each can reliably do a year” often determines real sales more than “how big the indicated population is in theory”.

Thread three: payment is the biggest commercial bottleneck — and 2025’s biggest breakthrough

CAR-T’s clinical value can be very high, but prices of RMB 990,000 to 1.29 million can almost never be solved by basic medical insurance — too expensive, and a one-off lump-sum expense, inherently in conflict with the NRDL’s logic of “broad coverage, basic protection”. A rough calculation shows how hard this conflict is: basic medical insurance money is a big pool raised year after year from all enrollees to cover common-disease medication for over a billion people, and every yuan of it has to justify “value for money” and “sustainability”. One CAR-T infusion at over a million yuan equals decades of contributions from an ordinary enrollee; even reimbursing only part of it, the pool cannot withstand such one-off expenses being replicated at scale. This is not a question of “willingness”, but a structural issue: “the actuarial logic of basic medical insurance cannot accommodate CAR-T”. So for the past few years, CAR-T payment has been stuck in fragmented channels — Huiminbao, city-customized insurance, commercial health insurance, charitable assistance and hospital installment plans — and whether a patient can get treatment has depended largely on whether they happened to buy the right insurance and live in a covered city; the same patient in a different city could be the difference between “affordable” and “unaffordable”.

And this payment channel is evolving fast — by 2026, the story had moved another big step forward. As of the end of June 2026, the preliminary review results for the 2026 lists published by the National Healthcare Security Administration showed that inati-cel and relma-cel had passed preliminary review for the basic NRDL — meaning CD19 CAR-T was knocking on the door of basic medical insurance for the first time (products already on the first commercial insurance list can use a “direct application” channel to try for the basic NRDL, which is exactly the route inati-cel took); Hrain’s and Precision Bio’s products passed preliminary review for the Commercial Health Insurance Innovative Drug List; and satri-cel, the solid tumor breakthrough, also entered the relevant application process. It must be stressed that “passing preliminary review” only earns entry to subsequent negotiations, and final inclusion is still separated by price negotiation; whether it gets in, and at what price, is still undecided. But the direction is already very clear: CAR-T payment is rapidly institutionalizing, moving from “fragmented commercial insurance and Huiminbao” to “layered coverage by national lists” — the commercial insurance list as a backstop, and basic medical insurance beginning to tentatively admit lower-priced products. Once this layered payment system runs smoothly, it will be the real switch deciding whether CAR-T can move from “affordable to a few” to “scaled uptake”.

The weight of this is that it gave, for the first time, a national-level answer to “how a million-yuan living drug can be caught by the payment system”, pushing CAR-T a big step from “the choice of a few wealthy families” toward “affordable if you have commercial insurance”. Whoever can get their product into these payment channels, and whoever can design plans patients can actually afford, holds the switch for uptake. One more intriguing detail: the global bestseller cilta-cel is not on this commercial insurance list — confirming again from the payment side the reality of its weak commercial presence in China. Whether, and when, it steps up domestic efforts remains to be seen.

Thread four: off-the-shelf therapies will keep squeezing CAR-T from the flank

This thread runs through both the CD19 and BCMA lanes. Bispecific antibodies, multispecific antibodies and ADCs are all “off-the-shelf” drugs: mass-produced, supplied from inventory, usable as soon as prescribed, with no need to make a batch of cells individually for each patient; the execution threshold is much lower, they don’t occupy the scarce collection–manufacturing–reinfusion chain, and patients don’t have to wait through a manufacturing cycle.

For CAR-T, this is a structural threat. In sequential treatment of relapsed/refractory lymphoma and myeloma, off-the-shelf drugs increasingly stand in front of or beside CAR-T, grabbing positions with “convenient, repeatable, no waiting for manufacturing”. Especially for rapidly progressing patients who can’t wait for a manufacturing cycle, physicians will naturally reach first for a bispecific that can be given immediately. The only weapon CAR-T has to hedge against this squeeze is its unique value proposition — one-time treatment, deep remission, and possibly long-term freedom from relapse or even functional cure. If CAR-T cannot keep proving with long-term follow-up data that “the durable benefit from one infusion is worth that complex process and high cost”, off-the-shelf therapies will nibble away at its usage bit by bit. This is also why this article keeps stressing “long-term follow-up data” — it is not academic icing on the cake, but CAR-T’s lifeline against off-the-shelf competition.

Thread five: a company’s composite capability matters more than single-product data

After the first four threads, one conclusion is clear: CAR-T is not a “clinical business” but a composite business of R&D + manufacturing + medical + hospital services + payment. A company that can only do clinical trials is not enough, nor is one that can only do commercial.

This explains why these 9 products show four company models, and why there are so many “R&D party + commercial party” pairings: IASO with Innovent, CARsgen with Huadong, Fosun with Kite/Gilead, Legend with J&J. In essence, each is filling in the capability it lacks — some lack a commercial network, some lack global capability, some lack capital. The adjustment of eque-cel’s rights, cilta-cel’s invisibility in China and zevor-cel’s outsourced commercialization are all footnotes to this thread — in the CAR-T race, a product with maxed-out data paired with a company with capability gaps still won’t make it. Conversely, the ones with real long-term advantage are companies that can connect product, manufacturing, hospital-end services and payment solutions into a closed loop. Single-product data decide whether you get a seat at the table; composite capability decides whether you laugh last.

Using the five threads as a yardstick and looking back at the companies behind these 9 products, one can roughly rank “who stands more firmly” in tiers. What is ranked here is not the level of product data, but the overall capability to turn a product into a sustainable business.

This tiering is not the endgame. CAR-T competition is only in the middle game, and the payment breakthrough, the price war and next-generation technology may all reshuffle the deck. But it shows at least one thing: in looking at Chinese CAR-T, you can’t just look at whose ORR is higher; you have to look at who has done the three hard, unglamorous things — manufacturing, centers, payment — solidly. Data are the entry qualification; engineering and commercial capability are the ranking.

The 9 products are the end of one stage and the start of the next. Looking ahead, three inflection points will truly rewrite this lane, and a brand-new continent is emerging.

Five years, nine products — from lymphoma to leukemia, from adults to children, from hematologic cancers to solid tumors — Chinese CAR-T has completed the “0 to 9” approval stage. This is a remarkable achievement — it proves that China can not only make world-class CAR-T fast and in quantity (cilta-cel selling nearly US$2 billion globally is the evidence), but can also be first to break open the registration door on the global problem of solid tumors (satri-cel’s breakthrough).

But the judgment this article wants to leave is: approval itself is depreciating fast. When CD19 has 5 products with converging efficacy, when all three BCMA players’ data are maxed out, when prices begin to fall from a million toward 200,000, “can it be approved” is no longer the life-or-death question. The real watershed is whether this one-batch-at-a-time, million-yuan-priced, ICU-dependent “living drug”, which also has to battle through testing and payment, can be turned into a medical product that is replicable, payable and manageable over the long term — whether vein-to-vein time can be pushed down, whether certified centers can be rolled out, whether it can get onto the commercial insurance list, and whether a company’s R&D, manufacturing, medical and commercial capabilities can be twisted into one rope.

That is also why this article started from “what CAR-T really is”: all its commercial problems are inevitable projections of its nature as a “living drug”; and all the decisive factors are hidden in how that nature is tamed. Whoever makes manufacturing stable, rolls out centers and gets payment negotiated turns a technological miracle into a sustainable business.

If you take away only three sentences after reading about these 9 products, I hope they are these:

For Chinese CAR-T, what the past five years earned was the entry ticket. What the next five years must dig is the moat. After nine products, the real race for Chinese CAR-T has only just begun.